Infervision Launches World's First and Only AI-4D Intelligent Surgical Planning System – Featuring Lung, Liver, and Kidney Modules

Recently, good news has emerged from the AI healthcare sector: Infervision’sLiver and Kidney Surgical ProductsApproved by the National Medical Products Administration (NMPA) as a Class III medical device. The surgical planning product approved this time isThe First and Only Surgical Planning Product for Liver and Kidney Procedures to Obtain an NMPA Class III Medical Device Certificate，Along with the previously approved Infervision Lung Surgery Planning product, both are the first AI applications to receive NMPA Class III certification in their respective indications.

Since then, Infervision hasSecured the First Regulatory Approval in Both Lung and Abdominal Surgical Planning Fields, realizing the "golden combination" of the thoracic and abdominal surgical planning suite, to facilitate the intelligent and precise development of China's surgical medical sector.

On Monday, April 15, at 19:30, the 54th edition of VCBeat Select New Product Review will feature Chen Kuan, Founder and Chairman of Infervision, and Wang Tong, VP of the Commercialization Division at Infervision, who will presentProduct Introduction: The World’s First and Only AI-4D Intelligent Surgical Planning System (Covering Lung, Liver, and Kidney) Independently Developed。

The World's First AI Application for Cancer Surgical Treatment Approved with an NMPA Class III Certificate

The World’s First and Only Lung Surgery Planning Product Approved with an NMPA Class III Certificate

(Can be formulated for thoracic surgeonsLung Surgery Plan(for reference)

The world's first and only liver surgery planning product to receive a Class III certification from the NMPA

(Can assist physicians in formulatingHepatic SurgerySurgical Plan)

The world's first and only kidney surgery planning product to receive an NMPA Class III certification

(Can assist physicians in formulatingRenal Surgical ProceduresSurgical Plan)

Scan the QR code on the poster to add our assistant and reserve a spot for the live broadcast.

Chen Kuan

Infervision Founder & Chairman

Senior Engineer, member of the China Democratic National Construction Association, Founder and Chairman of Infervision Medical Technology Co., Ltd. He pursued dual doctoral degrees in Finance and Economics at the University of Chicago in the United States, studying under four Nobel Laureates in Economics. In 2015, he took a leave of absence to return to China and establish Infervision.

Under the leadership of Chen Kuan, Infervision has received numerous accolades: it was named a Winner in the First Batch of AI Innovation Unveiling by the Ministry of Industry and Information Technology (MIIT) in 2019; in 2020, Infervision launched its first AI product for COVID-19 to support epidemic control efforts, earning a Letter of Appreciation from the National Health Commission and an Anti-Epidemic Certificate from the Department of Science and Technology of MIIT; it won the Beijing Science and Technology Progress Award in 2021; was recognized as a Beijing “Specialized, Refined, Differential, and Innovative” Little Giant Enterprise in 2022; received the Hubei Province Science and Technology Progress Award in 2023; and was designated as a National-Level “Specialized, Refined, Differential, and Innovative” Little Giant Enterprise.

Major Honors, Awards, and Titles: Beijing Distinguished Expert (Haiju Talent Program), Zhongguancun High-End Leading Talent (Gaoju Talent Program), Entrepreneurial Leading Talent (Haiying Talent Program), First Prize of the 8th “China Overseas Chinese Contribution Award”, Second Prize of Beijing Science and Technology Progress Award, and “National Advanced Individual in the Fight Against COVID-19 within the National Science and Technology System,” among others.

Social Positions: Vice Chairman of the First Council of the Imaging Committee, China Medical Equipment AI Alliance; Vice Chairman of the First Council of the Imaging Committee, China Medical Equipment AI Alliance; Vice Chairman of the Medical Artificial Intelligence Professional Committee, China Association for Medical Device Industry; Member of the 15th Executive Committee of the Beijing Federation of Industry and Commerce; Expert of the Special Expert Committee of the All-China Federation of Returned Overseas Chinese; Member of the Expert Advisory Committee of Zhongguancun Science City; Director of the Beijing-Tianjin-Hebei Entrepreneurs Alliance; Standing Committee Member of the Second Session of the Artificial Intelligence and Medical Robot Working Committee, China Association of Medical Equipment, etc.

Wang Tong

VP, Commercialization Division, Infervision

Bachelor of Science in Biomedical Engineering from Northeastern University; extensive experience in sales management within the healthcare sector, having served at industry-leading companies such as Johnson & Johnson, Medtronic, and Philips; possesses strong expertise in channel development and business expansion.

Infervision Medical Technology Co., Ltd. (hereinafter referred to as “Infervision”), founded in 2016, is a globally leading AI healthcare technology company committed to its mission of “AI for Better Health” and dedicated to building a hospital-wide, internationally renowned AI brand.

The Company adopts a “horizontal-vertical” and “internationalization” strategic layout to build a multi-dimensional product portfolio. Horizontally, it comprehensively covers multiple disease areas, including cancer (lung cancer, liver cancer, breast cancer), infectious diseases (pneumonia, tuberculosis), cardiovascular diseases (coronary heart disease), cerebrovascular diseases (stroke), and trauma (fractures). Vertically, it follows the patient care pathway, encompassing disease screening and diagnosis (InferRead series), disease intervention and treatment (InferOperate series), patient health management (InferCare series), and medical research (InferScholar and InferMatrix), thereby providing advanced, integrated smart healthcare solutions to governments, medical institutions, physicians, and patients.

As of December 2023, Infervision is the first and only Chinese AI healthcare technology company to have its products receive regulatory approval in China, the United States, the European Union, the United Kingdom, and Japan. Its products have been deployed in over 1,000 medical institutions across 25 countries worldwide.

“Artery Select New Product Launch” is a live-streaming series under “Artery Select” dedicated to supporting medical enterprises in launching innovative products, with the mission of facilitating the milestone launch of every medical innovation.

Scan the QR code below to contact the assistant and reserve a spot for the live stream.

(If already added, please contact the assistant proactively)